Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 17/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.41 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.41 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1236720 | 0.90 | PIK3CG (0.47) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1237555 | 0.88 | PIK3CG (0.46) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1236893 | 0.87 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1237551 | 0.86 | PIK3CG (0.46) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1236640 | 0.85 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1614199 | 0.85 | PIK3CG (0.43) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1614200 | 0.85 | PI4KB (0.44) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1237882 | 0.85 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1237117 | 0.85 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL1235188 | 0.83 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399497-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2013-03-19 | — | — | US | claimed |
| EP-1885716-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2012-11-07 | — | — | EP | claimed |
| US-20110086843-A1 | Thiazole Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | claimed |
| US-7879888-B2 | N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | claimed |
| US-20080221180-A1 | Thiazole Derivatives and Use Thereof | LABORATORIES SERONO SA (CH) | 2008-09-11 | — | — | US | claimed |
| EP-1885716-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | Laboratoires Serono SA (CH) | 2008-02-13 | — | — | EP | claimed |
| WO-2006125803-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | claimed |
| US-8399497-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2013-03-19 | — | — | US | disclosed |
| US-8399497-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2013-03-19 | — | — | US | disclosed |
| US-8399497-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2013-03-19 | — | — | US | disclosed |
| EP-1885716-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2012-11-07 | — | — | EP | disclosed |
| EP-1885716-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-20110086843-A1 | Thiazole Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086843-A1 | Thiazole Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-7879888-B2 | N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7879888-B2 | N-(4-methyl-5-{5-[(prop-2-yn-1-ylamino)sulfonyl]-2-thienyl}-1,3-thiazol-2-yl)acetamide; autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-20080221180-A1 | Thiazole Derivatives and Use Thereof | LABORATORIES SERONO SA (CH) | 2008-09-11 | — | — | US | disclosed |
| US-20080221180-A1 | Thiazole Derivatives and Use Thereof | LABORATORIES SERONO SA (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1885716-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | Laboratoires Serono SA (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006125803-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221180-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | PIK3CG 2526/4885PIK3CD 1844/4885PIK3CA 1647/4885 |
| US-20110086843-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | PIK3CG 2526/4885PIK3CD 1844/4885PIK3CA 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.